AETERNA ZENTARIS ANNOUNCES SETTLEMENT OF PREVIOUSLY DISCLOSED CLASS-ACTION LAWSUIT
The settlement remains subject to execution of final settlement documents and approval by the U.S. District Court for the District of New Jersey.
- The settlement remains subject to execution of final settlement documents and approval by the U.S. District Court for the District of New Jersey.
- Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests.
- Macrilen is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales.
- Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.